EGFR-IN-209 

EGFR-IN-209 (Compound 6g) is an orally active, selective EGFR^{Del19/T790M/C797S} inhibitor with an IC₅₀ of 0.056 μM. EGFR-IN-209 blocks the phosphorylation of EGFR and its downstream effector molecules (pMAPK, pAKT). EGFR-IN-209 induces Apoptosis. EGFR-IN-209 exhibits antitumor activity against Osimertinib (HY-15772)-resistant non-small cell lung cancer. EGFR-IN-209 can be used in research related to non-small cell lung cancer^[1].

EGFR-IN-209 (30 min) potently inhibits purified EGFR^{Del19/T790M/C797S} kinase, with an IC₅₀ of 0.056 μM^[1].
EGFR-IN-209 (100-300 nM; 24 h) potently inhibits the viability of PC-9^{Del19/T790M/C797S} cells, with an IC₅₀ value of 0.143 μM^[1].
EGFR-IN-209 (100-300 nM; 24-48 h) inhibits the migration of PC-9^{Del19/T790M/C797S} cells in scratch wound healing assays^[1].
EGFR-IN-209 (0.5-1.5 μM) inhibits the activation of EGFR and its downstream AKT/MAPK signaling pathway in PC-9^{Del19/EGFRT790M/C797S} cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR-IN-209 (5-10 mg/kg; p.o.; daily) achieves dose-dependent tumor growth inhibition in osimertinib (HY-15772)-resistant NSCLC xenograft models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

363.46

C₂₁H₂₅N₅O

3088042-00-3

OC1=CC=CC=C1C2=NC(NCCN3CCN(C)CC3)=C4C=CC=CC4=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chang H, et al. Structure-guided discovery of a potent 2-aryl-4-aminoquinazoline-based inhibitor overcoming osimertinib resistance driven by EGFR C797S mutation in NSCLC. Eur J Med Chem. 2026;311:118818.